Skip to Content

Clinical benefit of nivolumab plus cabozantinib 1st line advanced renal cell carcinoma across subgroups

The CheckMate 9ER study shows an improved PFS across all subgroups. The combination was approved by EMA in March 2021.

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top